In type 1 diabetes (T1D) the body’s own immune system attacks and destroys the insulin-producing cells (β-cells) in the pancreas. This leads to a lack of insulin, which is essential for regulating blood sugar levels. We now know that stress experienced by β-cellsplays a key role in triggering the body’s immune response in T1D. Therefore, identifying molecules that reduce β-cell stress and improve their health would have a significant positive impact on T1D treatment and patients’ outcome.
The aim of my project is to investigate the therapeutic potential of a protein called LGR4-ECD (Leucine-rich repeat-containing G protein-coupled receptor 4-extracellular domain). We believe LGR4-ECD acts by blocking a pathway that we have shown is bad for β-cell health as it increases death, decreases replication and function, in the context of T1D. We will test LGR4-ECD efficacy against stressors related to T1D in culture and in animal models. Ultimately, by better understanding how LGR4-ECD can improve β-cell health, my research project aims to establish new treatments for T1D. The hope is that our candidate molecule LGR4-ECD could help preserve β-cell health and function (their capability to secrete insulin) to treat T1D.
